Akira Higashimori

Dr. Akira Higashimori

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
NMNatsumi Maeda
Natsumi Maeda
AHAkira Higashimori
Akira Higashimori
DKDaijiro Kabata
Daijiro Kabata
IYIkki Yamamoto
Ikki Yamamoto
TYTsuyoshi Yanagida
Tsuyoshi Yanagida
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
INTRODUCTION: No bowel preparation (BP) for colonoscopy achieves optimal efficacy and tolerability. Combining polyethylene glycol plus ascorbic acid (PEG-Asc) with adjuvants has been explored to enhance cleansing efficacy and reduce the required volume. The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc. METHODS: A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy. The primary outcome was adequate BP, evaluated using the Boston Bowel Preparation Scale. Analyses were stratified based on low-risk and high-risk groups for inadequate BP. RESULTS: Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733). The 1L-PEG/AL demonstrated higher adequate BP rates (92% vs 86%, P = 0.001) compared with 1L-PEG/AS. Both groups experienced similar adverse events and expressed high willingness for repeat BP (83% vs 81%, P = 0.49). In high-risk patients (n = 892), 1L-PEG/AL had significantly higher adequate BP rates (94% vs 86%, P < 0.001), whereas rates were comparably high in low-risk patients (n = 539) (94% vs 94%, P = 0.66). DISCUSSION: The linaclotide regimen was superior to the senna regimen reagrding BP efficacy without reducing tolerability. It can be a promising new option for BP, especially in patients at a high risk of inadequate BP.

26 December 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
KOKoji Otani
Koji Otani
DHDao Viet Hang
Dao Viet Hang
RPRapat Pittayanon
Rapat Pittayanon
HLHenry Liu
Henry Liu
KCKee Huat Chuah
Kee Huat Chuah
TAThe Upper GI Focus Group of the APAGE‐ELC
The Upper GI Focus Group of the APAGE‐ELC
Background and Aim: Gastric cancer (GC)‐related incidence and mortality rates remain high owing to Helicobacter pylori infection in Asia, and the importance of primary and secondary prevention of GC has been well recognized. We aimed to investigate the extent of overall agreement among clinicians in the Asia‐Pacific region regarding the management of H. pylori infection.Methods: The Upper Gastrointestinal (GI) Focus Group of the Asian Pacific Association of Gastroenterology‐Emerging Leaders Committee developed an international survey, which was distributed to 98 clinicians in the Asia‐Pacific region, compromising an online questionnaire focusing on the management of H. pylori infection.Results: Participants responded from Japan (15, 15.3%), Hong Kong (15, 15.3%), Thailand (33, 33.7%), Vietnam (23, 23.5%), Malaysia (4, 4.1%), Singapore (3, 3.1%), and others (5, 5.1%). The most common first‐line eradication regimen was clarithromycin (CAM) triple therapy, including proton pump inhibitor (PPI), amoxicillin (AMPC), and CAM (64.3%) for 14 days (70.4%). The most common second‐line eradication regimen was levofloxacin (LVX) triple therapy, including PPI, AMPC, and LVX (22.4%) for 14 days (67.3%). Eradication therapy was deemed necessary for all asymptomatic adults and minors (aged ≤ 17 years) currently infected with H. pylori by 81.6% and 64.3% of respondents, respectively, with 82.7% considering upper GI endoscopy for GC screening useful in the secondary prevention of GC.Conclusion: There appears to be a growing consensus among clinicians, acknowledging the necessity of eradication therapy. We anticipate that this study will establish a new benchmark in preventive medicine aimed at eradicating GC in the Asia‐Pacific region.

10 December 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
SKSatoshi Kosaka
Satoshi Kosaka
YNYuji Nadatani
Yuji Nadatani
AHAkira Higashimori
Akira Higashimori
KOKoji Otani
Koji Otani
KFKosuke Fujimoto
Kosuke Fujimoto
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
We determined the bone mineral density (BMD) and the expression of serum bone formation marker (procollagen type I N-terminal propeptide: PINP) and bone resorption marker (C-terminal telopeptide of collagen: CTX) by ELISA to evaluate ovariectomy-induced osteoporosis in ovariectomized (OVX) mice. The intestinal microbiota of the mice was assessed using 16S rRNA gene sequencing. OVX mice exhibited a lower BMD of 87% with higher serum levels of CTX and PINP compared to sham-operated (sham) mice. The cecum microbiome of OVX mice showed lower bacterial diversity than that of sham mice. TNFα mRNA levels in the colon were 1.6 times higher, and zonula occludens-1 mRNA and protein expression were lower in OVX mice than in sham mice, suggesting that ovariectomy induced inflammation and increased intestinal permeability. Next, we used antibiotic treatment followed by fecal microbiota transplantation (FMT) to remodel the gut microbiota in the OVX mice. A decrease in PINP was observed in antibiotic-treated mice, while there was no change in BMD or CTX between mice with and without antibiotic treatment. Oral transplantation of the luminal cecal content of OVX or sham mice to antibiotic-treated mice did not affect the BMD or PINP and CTX expression. Additionally, transplantation of the luminal contents of OVX or sham mice to antibiotic-treated OVX mice had similar effects on BMD, PINP, and CTX. In conclusion, although ovariectomy induces dysbiosis in the colon, the changes in the gut microbiota may only have a minor role in ovariectomy-induced osteoporosis.

30 July 2021 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
NMNatsumi Maeda
Natsumi Maeda
AHAkira Higashimori
Akira Higashimori
MNMasami Nakatani
Masami Nakatani
YMYuki Mizuno
Yuki Mizuno
YNYoshihiro Nakamura
Yoshihiro Nakamura
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
A 50–100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are avai...

26 January 2023 in Digestive Endoscopy
Verified
Journal Article
Closed access
NMNatsumi Maeda
Natsumi Maeda
AHAkira Higashimori
Akira Higashimori
MNMasami Nakatani
Masami Nakatani
KJKagami Jinnai
Kagami Jinnai
DKDaiyu Kin
Daiyu Kin
YFYasuhiro Fujiwara
Yasuhiro Fujiwara

10 October 2024 in The Lancet
Verified
Journal Article
Closed access
AHAkira Higashimori
Akira Higashimori
NMNatsumi Maeda
Natsumi Maeda
MKMasahiro Kato
Masahiro Kato
KKKenichi Kohashi
Kenichi Kohashi
YFYasuhiro Fujiwara
Yasuhiro Fujiwara